CY1123176T1 - Antimikpobiako πεπτιδιο και συνθεσεις αυτου - Google Patents
Antimikpobiako πεπτιδιο και συνθεσεις αυτουInfo
- Publication number
- CY1123176T1 CY1123176T1 CY20201100692T CY201100692T CY1123176T1 CY 1123176 T1 CY1123176 T1 CY 1123176T1 CY 20201100692 T CY20201100692 T CY 20201100692T CY 201100692 T CY201100692 T CY 201100692T CY 1123176 T1 CY1123176 T1 CY 1123176T1
- Authority
- CY
- Cyprus
- Prior art keywords
- present
- compositions
- peptide
- antimicrobial
- hiv
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Η παρούσα εφεύρεση παρέχει αντιμικροβιακά πεπτίδια που επιδεικνύουν ευρύ φάσμα αντιμικροβιακής δράσης σε βακτήρια θετικά κατά gram και αρνητικά κατά gram, καθώς και σε μύκητες, ευρωτομύκητες και ιούς. Το αντιμικροβιακό πεπτίδιο της εφεύρεσης είναι ένα κατιονικό πεπτίδιο και μπορεί να περιέχει μια αλληλουχία HIV-TAT ή μια αντίστροφη αλληλουχία HIV-TAT ή ένα παράγωγο αυτής. Η παρούσα εφεύρεση παρέχει επίσης αντιμικροβιακές συνθέσεις που περιέχουν το κατιονικό πεπτίδιο. Τέτοιες συνθέσεις είναι ιδιαίτερα χρήσιμες για τοπική εφαρμογή στο δέρμα, τα μαλλιά, τα νύχια, τον κόλπο, την ουρήθρα, το αυτί, τη στοματική κοιλότητα, τη ρινική δίοδο, το αναπνευστικό σύστημα, την οφθαλμική περιοχή και διάφορες περιοχές του βλεννογόνου. Οι συνθέσεις της παρούσας εφεύρεσης βελτιώνουν την κατάσταση ή/και την όψη της θεραπευόμενης περιοχής και είναι κατάλληλες για μακρά ή/και τακτική χρήση, για παράδειγμα, για την πρόληψη μικροβιακής λοίμωξης ή για την αποτροπή της επανεμφάνισης αυτής. Η παρούσα εφεύρεση παρέχει επίσης κιτ για χρήση στη βελτίωση της κατάστασης ή της όψης του δέρματος, του νυχιού ή της θεραπευόμενης περιοχής. Αυτά τα κιτ μπορούν να διευκολύνουν τη χρήση, τη μακρά αποθήκευση ή/και την αποτελεσματικότητα των συνθέσεων.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95205907P | 2007-07-26 | 2007-07-26 | |
EP08826608.5A EP2178549B1 (en) | 2007-07-26 | 2008-07-28 | Antimicrobial peptide and compositions thereof |
PCT/US2008/071350 WO2009015385A1 (en) | 2007-07-26 | 2008-07-28 | Antimicrobial peptide, compositions , and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1123176T1 true CY1123176T1 (el) | 2021-10-29 |
Family
ID=40281862
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161101296T CY1118503T1 (el) | 2007-07-26 | 2016-12-14 | Αντιμικροβιακο πεπτιδιο και συνθεσεις αυτου |
CY20201100692T CY1123176T1 (el) | 2007-07-26 | 2020-07-27 | Antimikpobiako πεπτιδιο και συνθεσεις αυτου |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161101296T CY1118503T1 (el) | 2007-07-26 | 2016-12-14 | Αντιμικροβιακο πεπτιδιο και συνθεσεις αυτου |
Country Status (25)
Country | Link |
---|---|
US (1) | US8623811B2 (el) |
EP (3) | EP3741380A1 (el) |
JP (5) | JP5401457B2 (el) |
KR (4) | KR101717275B1 (el) |
CN (2) | CN102872447B (el) |
AU (1) | AU2008278593B2 (el) |
BR (3) | BRPI0813627B1 (el) |
CA (1) | CA2694046C (el) |
CO (1) | CO6260098A2 (el) |
CR (1) | CR11239A (el) |
CY (2) | CY1118503T1 (el) |
DK (2) | DK2178549T3 (el) |
ES (2) | ES2609914T3 (el) |
HK (1) | HK1180237A1 (el) |
HR (1) | HRP20161722T1 (el) |
HU (1) | HUE031136T2 (el) |
IL (3) | IL203173A (el) |
LT (1) | LT2178549T (el) |
MX (1) | MX2010000916A (el) |
NZ (1) | NZ582459A (el) |
PL (1) | PL2178549T3 (el) |
PT (2) | PT2178549T (el) |
SG (1) | SG188128A1 (el) |
SI (1) | SI2178549T1 (el) |
WO (1) | WO2009015385A1 (el) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100093639A1 (en) * | 2006-12-29 | 2010-04-15 | Revance Therapeutics, Inc. | Transport Molecules Using Reverse Sequence HIV-TAT Polypeptides |
PT2178549T (pt) * | 2007-07-26 | 2016-12-20 | Revance Therapeutics Inc | Péptido antimicrobiano e suas composições |
US8933013B2 (en) | 2007-12-05 | 2015-01-13 | Nono Inc. | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
US8080518B2 (en) * | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
ES2524312T3 (es) | 2008-03-14 | 2014-12-05 | Allergan, Inc. | Ensayos de actividad de serotipo A de toxina botulínica de base inmunológica |
DK2379104T3 (en) | 2008-12-31 | 2018-04-30 | Revance Therapeutics Inc | Injectable botulinum toxin formulations |
EP2413947B1 (en) | 2009-04-01 | 2020-04-29 | Revance Therapeutics, Inc. | Methods and compositions for treating skin conditions associated with vascular hyper-reactivity |
SG177357A1 (en) | 2009-06-25 | 2012-02-28 | Revance Therapeutics Inc | Albumin-free botulinum toxin formulations |
US8387798B1 (en) | 2012-04-27 | 2013-03-05 | Abdulmohsen E. A. H. Al-Terki | Mutiple oral and nasal surgical procedures method and kit |
US10022083B2 (en) | 2011-06-02 | 2018-07-17 | Abdulmohsen E. A. H. Al-Terki | Multiple oral and nasal surgical procedures method and kit |
FR2997304B1 (fr) | 2012-10-26 | 2017-07-07 | Isp Investments Inc | Utilisation d’un extrait de lin, en tant qu’agent actif activateur de la synthese de peptides antimicrobiens |
CA2889833A1 (en) | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and methods for safe treatment of rhinitis |
US20140242110A1 (en) * | 2013-02-28 | 2014-08-28 | Dt Scimed, Llc | Dose, localization, and formulation of botulinum toxins in skin and muscle |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
US11684567B2 (en) | 2015-08-05 | 2023-06-27 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
US11793783B2 (en) | 2015-08-05 | 2023-10-24 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
EP4115897A1 (en) * | 2015-09-17 | 2023-01-11 | Contrafect Corporation | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby |
US10105381B2 (en) * | 2016-05-23 | 2018-10-23 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
US10144767B2 (en) * | 2016-08-18 | 2018-12-04 | Board Of Regents Of The University Of Nebraska | Anti-microbial peptides and coatings |
CA3044219A1 (en) * | 2016-11-21 | 2018-05-24 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
EP3675900A4 (en) | 2017-08-28 | 2021-05-05 | Revance Therapeutics, Inc. | TRANSMUCOSAL BOTULINUM TOXIN COMPOSITIONS, KITS, AND METHODS FOR TREATMENT OF BLADDER DISORDER |
CN107353334B (zh) * | 2017-08-30 | 2020-02-07 | 四川大学 | 基于唾液富酪蛋白的仿生防龋多肽、其衍生物和盐及应用 |
CN107556374B (zh) * | 2017-08-30 | 2020-02-07 | 四川大学 | 唾液富脯蛋白仿生防龋功能多肽、其衍生物和盐及其应用 |
JP7266202B2 (ja) * | 2018-02-19 | 2023-04-28 | 株式会社ファンケル | 化粧料及び抗炎症剤 |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744166A (en) * | 1989-02-25 | 1998-04-28 | Danbiosyst Uk Limited | Drug delivery compositions |
US5804604A (en) * | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
US5652122A (en) * | 1989-12-21 | 1997-07-29 | Frankel; Alan | Nucleic acids encoding and methods of making tat-derived transport polypeptides |
WO1993021941A1 (en) * | 1992-04-23 | 1993-11-11 | Allelix Biopharmaceuticals Inc. | Treatment of herpesvirus infection |
JP2702285B2 (ja) | 1992-08-21 | 1998-01-21 | バイオジェン,インコーポレイテッド | Tat由来の輸送ポリペプチド |
AU685862B2 (en) * | 1993-10-22 | 1998-01-29 | Allelix Biopharmaceuticals Inc. | Treatment of cytomegalovirus infection |
EP1421948B1 (en) | 1993-12-28 | 2008-10-08 | Allergan, Inc. | Use of botulinum toxins against sweating in humans |
US6232295B1 (en) | 1994-10-12 | 2001-05-15 | Jon Faiz Kayyem | Cell-specific contrast agent and gene delivery vehicles |
GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
DE69637731D1 (de) * | 1995-08-23 | 2008-12-11 | Univ British Columbia | Antimikrobielle kationische peptide und methoden zu ihrer identifizierung |
US6043218A (en) * | 1996-10-22 | 2000-03-28 | Medical University Of South Carolina | Positively charged non-natural amino acids, methods of making thereof, and use thereof in peptides |
GB9623051D0 (en) | 1996-11-06 | 1997-01-08 | Schacht Etienne H | Delivery of DNA to target cells in biological systems |
JP2002505077A (ja) * | 1997-12-10 | 2002-02-19 | ワシントン大学 | 抗病原体システムおよびその使用方法 |
WO1999031261A1 (en) * | 1997-12-12 | 1999-06-24 | Onyx Pharmaceuticals, Inc. | SELECTIVE KILLING AND DIAGNOSIS OF p53+ NEOPLASTIC CELLS |
BR9914891A (pt) | 1998-10-27 | 2001-07-17 | Mayo Foundation | Processos para aperfeiçoamento de cura de ferimento |
JP2002531113A (ja) | 1998-12-10 | 2002-09-24 | ワシントン大学 | 蛋白質の形質導入システムおよびその使用法 |
KR100638150B1 (ko) | 1998-12-23 | 2006-10-26 | 이데아 악티엔게젤샤프트 | 생체내에서 국부적인 비침습성 용도로 사용되는 개선된 제제 |
US7056656B1 (en) * | 1999-01-25 | 2006-06-06 | University Of Medicine And Dentistry Of New Jersey | Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA |
US20030236214A1 (en) * | 1999-06-09 | 2003-12-25 | Wolff Jon A. | Charge reversal of polyion complexes and treatment of peripheral occlusive disease |
US7008924B1 (en) * | 1999-07-21 | 2006-03-07 | Amgen, Inc. | VGF fusion polypeptides |
US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US6544548B1 (en) * | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
US6844324B1 (en) * | 1999-11-12 | 2005-01-18 | Massachusetts Institute Of Technology | Modular peptide mediated intracellular delivery system and uses therefore |
US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
US6670322B2 (en) * | 2000-06-01 | 2003-12-30 | Wisconsin Alumni Research Foundation | Method of targeting pharmaceuticals to motor neurons |
US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
US20030215412A1 (en) * | 2000-07-21 | 2003-11-20 | Essentia Biosystems, Inc. | Induction of hair growth with vascular endothelial growth factor |
JP5610659B2 (ja) * | 2000-07-21 | 2014-10-22 | ルバンス セラピュティックス インク.Revance Therapeutics,Inc. | 多成分生物学的輸送システム |
US6696038B1 (en) * | 2000-09-14 | 2004-02-24 | Expression Genetics, Inc. | Cationic lipopolymer as biocompatible gene delivery agent |
US20020127247A1 (en) * | 2000-11-17 | 2002-09-12 | Allergen Sales, Inc. | Modified clostridial neurotoxins with altered biological persistence |
ATE437647T1 (de) | 2001-02-16 | 2009-08-15 | Cellgate Inc | Transporter mit beabstandeten arginin-teilchen |
CA2446458A1 (en) * | 2001-05-09 | 2002-11-14 | Yale University | Toll/interleukin-1 receptor adaptor protein (tirap) |
US7060498B1 (en) * | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
EP1461084A2 (en) * | 2001-12-11 | 2004-09-29 | The Board Of Trustees Of The Leland Stanford Junior University | Guanidinium transport reagents and conjugates |
WO2003072049A2 (en) | 2002-02-21 | 2003-09-04 | Essentia Biosystems, Inc. | Induction of hair growth with vascular endothelial growth factor |
US20030215395A1 (en) * | 2002-05-14 | 2003-11-20 | Lei Yu | Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
JP4154218B2 (ja) * | 2002-11-27 | 2008-09-24 | 寛紀 高麗 | 新規抗菌性ポリペプチドとその利用 |
IL153557A0 (en) * | 2002-12-19 | 2003-07-06 | Yitzchak Hillman | Antibodies and antagonists to antimicrobial peptides for the purpose of treating, inhibiting and preventing auto immune diseases |
NZ540506A (en) * | 2002-12-19 | 2008-09-26 | Yitzchak Hillman | Disease treatment via antimicrobial peptide inhibitors |
AU2004209981B2 (en) * | 2003-02-01 | 2009-02-26 | Janssen Sciences Ireland Uc | Active immunization to generate antibodies to soluble A-beta |
WO2004084805A2 (en) * | 2003-03-19 | 2004-10-07 | The J. David Gladstone Institutes | Acetylated tat polypeptides and methods of use thereof |
US7125842B2 (en) * | 2003-04-07 | 2006-10-24 | Canbas Co. Ltd. | Anti-fungal compounds and methods of use |
MXPA06002828A (es) * | 2003-09-12 | 2006-06-23 | Univ British Columbia | Efectores de determinacion de inmunidad innata. |
JP2005120050A (ja) * | 2003-10-20 | 2005-05-12 | Toagosei Co Ltd | 新規抗菌性ペプチドとその利用 |
PT2985039T (pt) | 2004-03-03 | 2018-11-09 | Revance Therapeutics Inc | Aplicação tópica e administração transdérmica de toxinas botulínicas |
EP1734984A4 (en) * | 2004-03-03 | 2009-07-29 | Revance Therapeutics Inc | COMPOSITIONS AND METHODS FOR TOPICAL DIAGNOSIS AND THERAPEUTIC TRANSPORT |
PT1778720E (pt) * | 2004-08-18 | 2010-11-29 | Novabiotics Ltd | Péptidos antimicrobianos compreendendo um motivo com arginina e/ou lisina |
EP1656951A1 (en) * | 2004-11-12 | 2006-05-17 | Xigen S.A. | Conjugates with enhanced cell uptake activity |
WO2006050611A1 (en) | 2004-11-12 | 2006-05-18 | The University Of British Columbia | Antimicrobial peptides |
EP1661912A1 (en) | 2004-11-29 | 2006-05-31 | Xigen S.A. | Fusion protein comprising a BH3-domain of a BH3-only protein |
JP4730584B2 (ja) * | 2004-12-06 | 2011-07-20 | 東亞合成株式会社 | 抗菌ペプチド及びその利用 |
JP2006238751A (ja) * | 2005-03-02 | 2006-09-14 | Toagosei Co Ltd | ベロ毒素結合性を有する抗菌ペプチド及びその利用 |
ATE507236T1 (de) | 2005-03-03 | 2011-05-15 | Revance Therapeutics Inc | Zusammensetzungen und methoden zur topischen anwendung und zur transdermalen verabreichung eines oligopeptids |
RU2007136616A (ru) | 2005-03-03 | 2009-04-10 | Риванс Терапьютикс, Инк. (Us) | Композиция и способ для местного применения и чрескожного введения ботулинового токсина |
KR20080006568A (ko) | 2005-03-30 | 2008-01-16 | 레반스 테라퓨틱스, 아이엔씨. | 여드름 치료용 조성물 및 방법 |
EP1948230A4 (en) | 2005-11-17 | 2010-03-10 | Revance Therapeutics Inc | COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL ADMINISTRATION OF BOTULINUM TOXIN CONTAINING LESS NON-TOXIC PROTEINS |
WO2008082889A2 (en) | 2006-12-29 | 2008-07-10 | Revance Therapeutics, Inc. | Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from hiv-tat |
US20100093639A1 (en) | 2006-12-29 | 2010-04-15 | Revance Therapeutics, Inc. | Transport Molecules Using Reverse Sequence HIV-TAT Polypeptides |
PT2178549T (pt) * | 2007-07-26 | 2016-12-20 | Revance Therapeutics Inc | Péptido antimicrobiano e suas composições |
DK2379104T3 (en) | 2008-12-31 | 2018-04-30 | Revance Therapeutics Inc | Injectable botulinum toxin formulations |
-
2008
- 2008-07-28 PT PT88266085T patent/PT2178549T/pt unknown
- 2008-07-28 KR KR1020157019647A patent/KR101717275B1/ko active IP Right Grant
- 2008-07-28 MX MX2010000916A patent/MX2010000916A/es active IP Right Grant
- 2008-07-28 PT PT161840947T patent/PT3120862T/pt unknown
- 2008-07-28 SG SG2013009832A patent/SG188128A1/en unknown
- 2008-07-28 BR BRPI0813627-0A patent/BRPI0813627B1/pt active IP Right Grant
- 2008-07-28 EP EP20166266.5A patent/EP3741380A1/en active Pending
- 2008-07-28 ES ES08826608.5T patent/ES2609914T3/es active Active
- 2008-07-28 JP JP2010518431A patent/JP5401457B2/ja not_active Expired - Fee Related
- 2008-07-28 PL PL08826608T patent/PL2178549T3/pl unknown
- 2008-07-28 CN CN201210375756.5A patent/CN102872447B/zh active Active
- 2008-07-28 AU AU2008278593A patent/AU2008278593B2/en active Active
- 2008-07-28 ES ES16184094T patent/ES2805225T3/es active Active
- 2008-07-28 EP EP16184094.7A patent/EP3120862B1/en active Active
- 2008-07-28 WO PCT/US2008/071350 patent/WO2009015385A1/en active Application Filing
- 2008-07-28 KR KR1020107003133A patent/KR101722038B1/ko active IP Right Grant
- 2008-07-28 DK DK08826608.5T patent/DK2178549T3/en active
- 2008-07-28 KR KR1020177002763A patent/KR20170016031A/ko not_active Application Discontinuation
- 2008-07-28 LT LTEP08826608.5T patent/LT2178549T/lt unknown
- 2008-07-28 DK DK16184094.7T patent/DK3120862T3/da active
- 2008-07-28 BR BR122019000258-4A patent/BR122019000258B1/pt active IP Right Grant
- 2008-07-28 BR BR122019000266-5A patent/BR122019000266B1/pt active IP Right Grant
- 2008-07-28 CA CA2694046A patent/CA2694046C/en active Active
- 2008-07-28 US US12/669,705 patent/US8623811B2/en active Active
- 2008-07-28 CN CN200880100641.7A patent/CN101842107B/zh active Active
- 2008-07-28 EP EP08826608.5A patent/EP2178549B1/en active Active
- 2008-07-28 NZ NZ582459A patent/NZ582459A/en unknown
- 2008-07-28 HU HUE08826608A patent/HUE031136T2/en unknown
- 2008-07-28 KR KR1020187007958A patent/KR102088949B1/ko active IP Right Grant
- 2008-07-28 SI SI200831732T patent/SI2178549T1/sl unknown
-
2010
- 2010-01-06 IL IL203173A patent/IL203173A/en active IP Right Grant
- 2010-01-27 CR CR11239A patent/CR11239A/es not_active Application Discontinuation
- 2010-02-26 CO CO10023449A patent/CO6260098A2/es not_active Application Discontinuation
-
2012
- 2012-12-20 IL IL223784A patent/IL223784A/en active IP Right Grant
- 2012-12-20 IL IL223785A patent/IL223785A/en active IP Right Grant
-
2013
- 2013-06-28 HK HK13107613.7A patent/HK1180237A1/zh unknown
- 2013-10-28 JP JP2013222846A patent/JP5965884B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-04 JP JP2016132290A patent/JP2017002057A/ja active Pending
- 2016-12-14 CY CY20161101296T patent/CY1118503T1/el unknown
- 2016-12-14 HR HRP20161722TT patent/HRP20161722T1/hr unknown
-
2018
- 2018-08-17 JP JP2018153719A patent/JP6722241B2/ja active Active
-
2020
- 2020-06-19 JP JP2020105975A patent/JP2020169190A/ja active Pending
- 2020-07-27 CY CY20201100692T patent/CY1123176T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123176T1 (el) | Antimikpobiako πεπτιδιο και συνθεσεις αυτου | |
CY1121447T1 (el) | Συνθεσεις για αυξηση δραστηριοτητας τελομερασης | |
CY1121551T1 (el) | Φαρμακευτικη ή καλλυντικη συνθεση για τη θεραπεια της αλωπεκιας | |
ES2582555T3 (es) | Conservantes para composiciones cosméticas, de tocador y farmacéuticas | |
ITMI20041550A1 (it) | Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide | |
HUP0202235A2 (hu) | Tartósított gyógyászati készítmények | |
WO2006121610A3 (en) | Personal care compositions and methods for their use | |
BRPI0413427A (pt) | derivados de piridilpirrol ativos como inibidores da cinase | |
ATE533795T1 (de) | Neutralisiertes kationisches polymer, zusammensetzung mit dem besagten polymer und kosmetisches behandlungsverfahren | |
DE60213449D1 (de) | Zusammensetzungen enthaltend ein ethanolaminderivat sowie organische metallsalze | |
WO2014102596A3 (en) | Cyclic cationic peptides with antibmicrobial activity | |
BRPI0405939A (pt) | Formulações antibacterianas de uso tópico | |
WO2008029064A3 (fr) | Utilisation topique d'un extrait peptidique de soja et/ou de ble comme agent photoprotecteur | |
NO20065662L (no) | Esterlinkede makrolider nyttige for behandlingen av mikrobielle infeksjoner | |
CN102046009A (zh) | 用于甲真菌治疗的组合物和方法 | |
BRPI0411534A (pt) | derivados de lincomicina com atividade antimicrobiana | |
DE602005025495D1 (de) | Derivate einer arylsulfonamidosubstituierten hydroxamsäure als matrixmetalloproteinaseinhibitoren | |
DE502005010850D1 (de) | Antibakterielle amid-makrozyklen iv | |
NZ590878A (en) | Antimicrobial gel formulations comprising an halogenated amine compound dispersed in a poly(acrylic acid) water-swellable polymer | |
DE60034879T8 (de) | Lantibiotikum | |
BRPI0519752A2 (pt) | compostos peptÍdicos | |
ATE285786T1 (de) | Säugetierabkömmliche peptide zur behandlung von mikrobiellen infektionen | |
WO2007082864A3 (en) | Use of chavicol as an antiseptic | |
BR112014007491A2 (pt) | sequências de aminoácidos para o controle de patógenos | |
DE502004005924D1 (de) | Antimykotisch wirksame nagellackformulierungen mit substituierten 2-aminothiazolen als wirkstoff |